Welcome to our dedicated page for Gritstone Bio news (Ticker: GRTSQ), a resource for investors and traders seeking the latest updates and insights on Gritstone Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gritstone Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gritstone Bio's position in the market.
Gritstone bio (OTC: GRTSQ) reported updated Phase 2 data for GRANITE, its immunotherapy for first-line microsatellite stable colorectal cancer. The study showed a 27% relative risk reduction of progression or death with GRANITE versus control in all treated population, and a 50% relative risk reduction in the low ctDNA subgroup. As of October 2024, 28% of GRANITE patients and 13% of control patients remain progression-free. The company filed for Chapter 11 bankruptcy on October 10, 2024, and is pursuing bidders for its assets, with a bid deadline of December 4, 2024. Overall survival data is expected in 2H 2025.
FAQ
What is the current stock price of Gritstone Bio (GRTSQ)?
What is the market cap of Gritstone Bio (GRTSQ)?
